Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 225

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 225
---
 Neuropathology from Columbia University-College of Physicians & Surgeons, an M.B.A from Columbia Business School,
and a BA with honors in Biochemistry and Economics from Wellesley College. We believe that Dr. Chung is well-qualified to serve as
a director of our company based on Dr. Chung’s extensive corporate board and investment analysis experience.

Peter O’Rourke— Peter
O’Rourke has served as Lead Independent Director since July 2025. Since December 2018, Mr. O’Rourke has served
as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector. From November 2020-August 2022,
Mr. O’Rourke was President and Director for Western Magnesium, where he created the U.S. operations strategy and team
during the successful technology pilot phase of the company, and led enterprise and defense business development, government affairs,
and communications. From January 2017 to December 2018, Mr. O’Rourke served as the Acting Secretary and Chief of
Staff of the Department of Veteran Affairs. From May 2015 to July 2016, Mr. O’Rourke served as a principal of Calibre
Systems, Inc., a consulting firm. Mr. O’Rourke also served in both the U.S. Navy and Air Force. Mr. O’Rourke
served as Director for AXIM Biotechnologies from July 2020 to present. AXIM is a vertically integrated research and development company
focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic
tests. Mr. O’Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well
as a Master of Science in Logistics and Supply Chain Management from the United States Air Force’s Institute of Technology.
We believe that Mr. O’Rourke is well-qualified to serve as a director of our company based on Mr. O’Rourke’s
leadership and consulting experience in the healthcare industry.

Jack Stover —Jack
Stover has served as a director since July 2025. Since November 2018, Mr. Stover has been director, member of the compensation
committee, chairman of the audit committee, chairman of the special deal committee and recently Lead Independent Director of Traws Pharma
Inc. (TRAW) (formerly Onconova Therapeutics, Inc. (ONT